Fmr LLC Sells 412,549 Shares of Hill-Rom Holdings, Inc. (HRC)

Fmr LLC reduced its holdings in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 18.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,827,957 shares of the medical technology company’s stock after selling 412,549 shares during the period. Fmr LLC owned about 2.75% of Hill-Rom worth $172,559,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Oakbrook Investments LLC grew its holdings in shares of Hill-Rom by 34.5% in the third quarter. Oakbrook Investments LLC now owns 8,967 shares of the medical technology company’s stock worth $846,000 after purchasing an additional 2,300 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Hill-Rom in the second quarter worth approximately $10,392,000. Millennium Management LLC grew its holdings in shares of Hill-Rom by 32.3% in the second quarter. Millennium Management LLC now owns 583,635 shares of the medical technology company’s stock worth $50,975,000 after purchasing an additional 142,654 shares during the last quarter. State of Alaska Department of Revenue grew its holdings in shares of Hill-Rom by 14.5% in the third quarter. State of Alaska Department of Revenue now owns 7,674 shares of the medical technology company’s stock worth $724,000 after purchasing an additional 974 shares during the last quarter. Finally, Valeo Financial Advisors LLC grew its holdings in shares of Hill-Rom by 18,894.9% in the third quarter. Valeo Financial Advisors LLC now owns 95,924 shares of the medical technology company’s stock worth $8,065,000 after purchasing an additional 95,419 shares during the last quarter. Institutional investors and hedge funds own 82.59% of the company’s stock.

Several research analysts have recently issued reports on HRC shares. Barclays started coverage on shares of Hill-Rom in a report on Monday, October 15th. They issued an “equal weight” rating and a $95.00 target price on the stock. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. Zacks Investment Research cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. UBS Group started coverage on shares of Hill-Rom in a report on Tuesday, November 27th. They issued a “buy” rating and a $115.00 target price on the stock. Finally, Raymond James raised their target price on shares of Hill-Rom from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, November 5th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Hill-Rom has an average rating of “Buy” and a consensus price target of $104.00.

In related news, SVP Andreas G. Frank sold 7,454 shares of Hill-Rom stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $95.76, for a total value of $713,795.04. Following the sale, the senior vice president now owns 27,224 shares in the company, valued at $2,606,970.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.

NYSE:HRC opened at $92.76 on Friday. The firm has a market capitalization of $6.46 billion, a P/E ratio of 19.53, a P/E/G ratio of 1.34 and a beta of 0.94. Hill-Rom Holdings, Inc. has a twelve month low of $78.16 and a twelve month high of $99.81. The company has a current ratio of 1.74, a quick ratio of 1.30 and a debt-to-equity ratio of 1.11.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.12. The business had revenue of $759.20 million for the quarter, compared to analysts’ expectations of $750.90 million. Hill-Rom had a net margin of 8.86% and a return on equity of 21.10%. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share. As a group, analysts predict that Hill-Rom Holdings, Inc. will post 5.13 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 31st. Investors of record on Friday, December 14th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.86%. The ex-dividend date is Thursday, December 13th. Hill-Rom’s dividend payout ratio (DPR) is currently 16.84%.

TRADEMARK VIOLATION WARNING: “Fmr LLC Sells 412,549 Shares of Hill-Rom Holdings, Inc. (HRC)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/12/08/fmr-llc-sells-412549-shares-of-hill-rom-holdings-inc-hrc.html.

Hill-Rom Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Recommended Story: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply